Ann: Investor Webinar, page-8

Watched both presentations this week.

I'm very interested in their solutions for saliva and swab tests to be revealed later this year. This could create some significant I.P if it's anything like their blood-based solutions. The new Elion product looks fantastic.

Atomo will be the Apple for POCT, with ease of use, simplicity and accuracy at the forefront. Coupled with a digital telehealth enabled app this will be the gold standard for decentralised diagnostics.

This will be one of those investments you to look back on in 3-5 years and wish you bought and held. As John Kelly mentioned, the volatility and share price will sort itself out once annuity-style revenues become predictable.